

UCSF

UC San Francisco Previously Published Works

Title

Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria

Permalink

<https://escholarship.org/uc/item/1j54248n>

Journal

Journal of the American Heart Association, 12(1)

ISSN

2047-9980

Authors

Aeschbacher-Germann, Martina

Kaiser, Nathalie

Speierer, Alexandre

et al.

Publication Date

2023-01-03

DOI

10.1161/jaha.122.026551











Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

SYSTEMATIC REVIEW AND META-ANALYSIS

Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria

Martina Aeschbacher-Germann , MD; Nathalie Kaiser , MD; Alexandre Speierer , MD; Manuel R. Blum , MD, MSc; Douglas C. Bauer , MD; Cinzia Del Giovane , PhD; Drahomir Aujesky , MD, MSc; Baris Gencer , MD, MPH; Nicolas Rodondi , MD, MAS; Elisavet Moutzouri , MD, PhD

BACKGROUND: Randomized clinical trials (RCTs) might not be representative of the real-world population because of unreasonable exclusion criteria. We sought to determine which groups of patients are excluded from RCTs that included lipid-lowering therapy.

METHODS AND RESULTS: We retrieved all trials from the Cholesterol Treatment Trialists Collaboration and systematically searched for large (≥ 1000 participants) lipid-lowering therapy RCTs, defined as statins, ezetimibe, and PCSK9 inhibitors. We predefined groups: older adults (>70 or >75 years), women, non-Whites, chronic kidney failure, heart failure, immunosuppression, cancer, dementia, treated thyroid disease, chronic obstructive pulmonary disease, mental illness, atrial fibrillation, multimorbidity (≥ 2 chronic diseases), and polypharmacy. We counted the number of RCTs excluding patients of the predefined groups and meta-analyzed the prevalence of included patients to obtain pooled estimates with a random-effects model. We included 42 RCTs (298 605 patients). Eighty-one percent of trials excluded patients with severe and 76% those with moderate kidney failure. Seventy-one percent of trials excluded groups of women, 64% excluded patients with moderate to severe heart failure, 64% those with immunosuppressant conditions, 48% those with cancer, 29% those with dementia, and 29% of trials excluded older adults. The pooled prevalence for patients >70 years of age was 25% (95% CI, 0%–49%), 11% (3%–18%) for >75 years of age, and 51% (38%–63%) for multimorbidity.

CONCLUSIONS: The majority of lipid-lowering therapy trials excluded patients with common diseases, such as moderate-to-severe kidney disease or heart failure or with immunosuppression. Underrepresenting certain populations, including women and older adults, might lead to limited transportability of study results and uncertainty on possible side-effects and efficacy in these groups. Future trials should promote diversity in the recruitment strategies and improve equity in cardiovascular research.

REGISTRATION: URL: ClinicalTrials.gov; Unique Identifier: CRD42021253909.

Key Words: exclusion criteria ■ external validity ■ generalizability ■ lipid trials ■ multimorbidity ■ statins

Mortality from cardiovascular disease (CVD) is high, causing 8.9 million deaths worldwide by 2019,¹ $\approx 45\%$ of all deaths in Europe and 16% globally.² Primary and secondary CVD prevention measures, such as lifestyle changes or treatment with

lipid-lowering medication, can reduce CVD mortality. Guidelines widely recommend statins as secondary prevention.³ However, their benefits and harms are less clear for primary prevention, because the net benefit of statins on absolute risk reduction depends on

Correspondence to: Elisavet Moutzouri, MD, PhD, Bern University Hospital, Freiburgstrasse 18, Bern 3010, Switzerland. Email: elisavet.moutzouri@extern.insel.ch

Supplemental Material is available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.122.026551>

For Sources of Funding and Disclosures, see page 9.

© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- Patients with conditions such as severe renal dysfunction (creatinine clearance <30 mL/min), severe congestive heart failure, immunosuppressant conditions, dementia, and mental illness were often excluded in large lipid-lowering therapy trials, while more than two-thirds of all studies excluded groups of women.
- One-third of the trials excluded patients >75 years of age, with a pooled prevalence of elderly patients (>75 years of age) of only 11%, while no trial, even recent trials, listed multimorbidity or polypharmacy as exclusion or inclusion criterion, with a pooled prevalence of multimorbid patients (defined as ≥ 2 chronic diseases) of 51% (95% CI, 38%–63%), suggesting that we need more trials that specifically target these populations.

What Are the Clinical Implications?

- Most lipid-lowering trials excluded large groups of patients managed in clinical practice, which could possibly lead to uncertainty in treating these groups, while exclusion of groups of women may contribute to limited knowledge of the efficacy and safety of lipid-lowering therapy in women compared with men.

Nonstandard Abbreviations and Acronyms

CTTC	Cholesterol Treatment Trialists Collaboration
LLT	lipid-lowering therapy

the individual's baseline risk of CVD,^{3–5} and their use is more controversial.⁶

Evidence of the effects of statins on CVD risk might have been drawn from trials with selected patient groups that do not represent real-world demographics, as previously observed in RCTs in other research fields.^{7–10} Compared with community populations, RCTs less often represent patients with multimorbidity or older age, and these patient groups are often excluded from RCTs.^{11,12} Likewise, people with specific concomitant chronic diseases are commonly excluded.¹³ In addition, 1 study found that trials conducted between 2005 and 2015 investigating heart failure (HF), coronary artery disease, or acute coronary syndrome underrepresented women and found that sex-related differences may have a relevant impact on drug efficacy and safety.¹⁴ Exclusion of specific groups might explain possible differences between observed

rates of adverse effects in clinical practice compared with RCTs but might also explain possible different outcomes in certain populations.¹⁵

Limited data suggest that some groups of patients might have been excluded in early statin trials.^{9,16} Moreover, there is little evidence on the efficacy of statin treatment in the multimorbid, elderly population or those with polypharmacy.^{17–21} It is therefore crucial to investigate which patients were included in recent large lipid-lowering RCTs. Therefore, we performed a systematic review and a meta-analysis to assess the prevalence of different patient groups in these trials.²²

METHODS

Data Availability

Extracted data are available upon request to the corresponding author.

This systematic review followed a prespecified, published protocol and adhered to PRISMA (preferred reporting items for systematic review and meta-analysis protocols) guidelines.²³ Prospero registration: CRD42021253909.

Search Strategy and Selection Criteria

The 2019 meta-analysis of the CTTC (Cholesterol Treatment Trialists Collaboration) served as our baseline study. We retrieved all eligible studies mentioned on the homepage until May 2021.²⁴ To update the search, we searched Medline, Embase, and Cochrane Central for large (≥ 1000 participants) lipid-lowering RCTs published in English between January 1, 2015 and May 25, 2021 (Data S1). All trials with cardiovascular outcomes and a minimum 2-year follow-up were considered. We limited the search to the last 6 years (January 2015–May 25, 2021), because the CTTC updated their last meta-analysis²¹ on large statin trials until this date, with the latest included trial published in 2016. For nonstatin trials, the first published trial on cardiovascular outcomes was published in 2015.²⁵ For ezetimibe, the landmark trial on cardiovascular outcomes is IMPROVE-IT (The Improved Reduction of Outcomes: Vytroin Efficacy International Trial),²⁶ published in 2015.

We defined lipid-lowering trials as trials with drugs that are known to reduce cardiovascular risk (statins, ezetimibe, and proprotein convertase subtilisin kexin type 9 inhibitors). We restricted our review to randomized controlled trials with participants ≥ 18 years of age who received lipid-lowering drugs for primary or secondary prevention of CVD, with CVD and/or mortality as primary outcomes. We included all RCTs that compared a statin, ezetimibe, a proprotein convertase subtilisin kexin type 9 inhibitor or a combination of these drugs with one of the following: placebo, usual care,

no treatment, another lipid-lowering medication, or different dose. We excluded trials that did not report a cardiovascular primary outcome, trials that included duplicate data (eg, substudies of an already included original article), secondary analysis of subgroups of trials, post-trial follow-up studies, and ongoing trials. The supplemental index contains a full list of search terms and our search strategy (Data S1).

Two review authors (M.A. and A.S.) independently screened each study's title and abstract for eligibility. Then M.A. and A.S. independently screened the full text of potentially eligible studies, applied our exclusion list (Figure S1), and resolved disagreements through discussion. No third opinion was needed. When 1 study generated multiple publications, we included the main paper from the trial, which contained the most relevant data. If the main study referenced a separate publication describing baseline characteristics or study design, we included both publications, counted as 1 study. Because the present study was a meta-analysis and not an intervention study, no ethical approval or informed consent was required, as per the Declaration of Helsinki.

Data Collection and Management

One author (M.A.) extracted the data to an Excel spreadsheet, and a second reviewer (A.S.) independently checked the data, resolving disagreement by discussion. We extracted data on publication details (study name, author, and year of publication), characteristics of the study population (number of participants, primary or secondary prevention, baseline characteristics, demographics, inclusion and exclusion criteria, and prevalence of medical conditions and medication), characteristics of the intervention and the comparison groups (type and dosage of lipid-lowering medication or placebo, and comparison groups), and the study's primary outcome. We did not contact study investigators to ask for unreported data.

M.A. and A.S. used the Cochrane Risk of Bias 2 tool to assess the risk of bias for each study included in the analysis. Cochrane Risk of Bias 2 is a tool for randomized controlled trials structured into 5 domains of bias, focusing on different aspects of trial design, conduct, and reporting (bias because of allocation concealment and failures of randomization, bias because of deviations from intended interventions, bias because of missing outcome data, bias in measurement of the outcome, and bias in selection of the reported result). Based on the answers to the signaling questions, an algorithm judges the domains as "low," "some concerns," or "high risk" of bias.²⁷

We predefined the following patient groups: older adults (≥ 70 or ≥ 75 years of age), women, non-Whites, chronic kidney disease (CKD) defined as estimated

glomerular filtration rate < 45 mL/min (moderate) or estimated glomerular filtration rate < 30 mL/min (severe), HF according to New York Heart Association classification, immunosuppressant conditions, cancer, dementia, treated thyroid disease, chronic obstructive pulmonary disease, mental illness, atrial fibrillation, multimorbidity, and patients with polypharmacy. Because of the reporting of the age prevalence, we had to change our definition from $\geq 70/75$ years of age to $> 70/75$ years of age. We defined multimorbidity as ≥ 2 chronic conditions and polypharmacy as use of ≥ 5 drugs. Because most studies did not specifically report multimorbidity, we defined them by proxy. We gathered the prevalence data from the baseline table. If it was a secondary prevention trial, we assumed that 100% had the mentioned condition (we did not count hypercholesterolemia as a medical condition). We then checked the prevalence of the other mentioned conditions in the baseline table and assumed the minimum percentage of multimorbid patients by using the medical condition with the highest prevalence (ie, the minimum of multimorbid patients). If it was a primary prevention trial, we checked the baseline table for the prevalence of the mentioned conditions. If there were 2 conditions with a prevalence $> 50\%$, we assumed that the percentage $> 50\%$ must be the minimum amount of multimorbid patients. We set our limit at 50% (not 60% as defined in the protocol) to avoid underestimating the amount of multimorbid patients. We did not count the amount of mentioned chronic comorbidities and divide it by the amount of patients as described in the protocol, because it would overestimate the amount of multimorbid patients because diseases are not evenly distributed.

Data Synthesis and Analysis

We summarized baseline characteristics and inclusion and exclusion criteria in text and tables.

For each patient group, we calculated the percentage of studies that excluded the specific predefined group based on these criteria and baseline characteristics.

Because trials used different inclusion and exclusion criteria and defined groups differently, we categorized exclusion into 3 different subgroups. Trials that used clearly defined exclusion criteria for a specific patient group were classed as "clearly excluded." Trials that used clearly defined exclusion criteria to exclude a segment of a patient group were classed as "partially excluded" (eg, only participants with HF New York Heart Association III-IV were excluded). Trials that did not describe a specific patient group but circumscribed a medical condition were classed as "probably excluded" (eg, if a trial mentioned "other suspected serious physical illness" we assumed that they excluded patients with cancer or terminal renal failure).

When enough data were available, we meta-analyzed the prevalence of specific patient groups that were included in the trials. For the quantitative synthesis, we used a random effects model to meta-analyze the prevalence of these predefined groups across included studies; we transformed the data with Freeman-Tukey and, for each group, estimated the pooled prevalence with a 95% CI.^{28,29} Apart from the meta-analysis based on the Freeman-Tukey method, which provides a pooled prevalence in studies, called “the average rates” (ie, estimates the mean of the mean prevalence across studies), which has high heterogeneity because of difference in size between studies, we have also calculated the “overall rate,” which represents the prevalence in the population and is calculated by pooling all studies together (ie, assuming all studies are random samples from the population) and may provide more valid results under heterogeneity. The estimation of average rates is answering the question “What is the mean prevalence seen in studies?,” and the estimation of overall rate estimates the mean prevalence in the population of patients.³⁰

If the prevalence of a predefined group was 0% (n=0), we included the study in our meta-analysis. For the analysis in STATA, 0 was replaced by 0.01 as continuity correction. If the prevalence was 100%, n was replaced by n-0.01. Studies with an unknown number of participants per predefined group were excluded from the analysis. We estimated heterogeneity with the I^2 statistic and tau-squared. STATA 16 was used for all statistical analyses. The significance for the *P* value was set at <0.05.

Because of nonreporting, it was not possible to calculate pooled prevalence of all predefined groups (not possible for dementia, cancer, HF, immunosuppressant condition, treated thyroid disease, kidney failure, chronic obstructive pulmonary disease, mental illness, and atrial fibrillation), of multimorbidity defined as ≥ 3 chronic conditions, or of polypharmacy.

RESULTS

Description of Studies

We included 42 trials, totaling 298 605 patients. Thirty-two of the trials had been mentioned by the CTTC, of which 28 trials were from the CTTC Collaboration meta-analysis, 2 trials that were excluded from the CTTC’s meta-analysis because individual patient data were missing, and 2 that were added to the CTTC homepage in or before May 2021. Additionally, we added 10 individual trials from our systematic search. The trials comprised 34 statin trials, 4 trials investigated statin and ezetimibe, 1 only investigated ezetimibe, 2 trials investigated proprotein convertase subtilisin kexin type 9 inhibitors, and 1 trial investigated several lipid-lowering

medications. The setting of 11 trials was primary prevention, and 22 trials focused on secondary prevention. Nine trials included patients in both primary and secondary prevention. All trials specified their inclusion and exclusion criteria for age (>70/>75 years) and sex. See [Tables S1](#) through [S3](#) for the included studies, the baseline characteristics of included studies, and inclusion and exclusion of specific predefined patients’ group.

Risk of Bias of Included Studies

We found that 17 trials met the criteria for low risk of bias in all 5 domains after assessing them with the Cochrane RoB2 tool. Sixteen trials were at moderate risk. Nine trials scored at high risk of bias, including 3 trials for which 2 or 3 moderate risks accumulated ([Figure S2](#)).

Synthesis of Results

The percentages of studies excluding specific patients’ groups are presented in [Figure 1](#) with additional data in [Table S4](#), stratified as “partially excluded” and “clearly excluded.”

Patients with severe CKD were excluded in 65.9% (n=27) of the trials, while 80.5% (n=33) of the trials excluded these patients or part of this group (eg, exclusion criterion: patients with an estimated glomerular filtration rate <20 mL/min or less); 19.5% (n=8) of the trials excluded patients with moderate CKD while 75.6% (n=31) of the trials excluded patients with moderate CKD or part of this group (eg, nephrotic syndrome), and 7.3% (n=3) of the trials did not report whether patients with CKD were excluded or included ([Figure S3](#)).

The WOSCOPS (West of Scotland Coronary Prevention Study) trial excluded all women; 71.4% (n=30) of trials excluded groups of women (premenopausal, childbearing potential, pregnant, or lactating women); 21.4% (n=9) trials excluded all premenopausal women, 23.8% (n=10) of trials excluded premenopausal women if no (adequate) contraception, 2.4% (n=1) of trials excluded premenopausal women of childbearing potential, and 28.6% (n=12) of trials excluded pregnant or breastfeeding women.

One trial excluded all patients with HF,³¹ whereas 64.3% (n=27) of trials defined a specific stadium of HF as exclusion criterion ([Figure 1](#) and [Table S4](#)). More particularly, 2 trials excluded all patients with HF requiring treatment with digitalis, diuretics, or vasodilators. Two trials excluded all patients with HF New York Heart Association II-IV, whereas 10 excluded all patients with HF New York Heart Association III-IV. Seven trials excluded patients with an ejection fraction of <25% or <30%. Four trials excluded patients with decompensated HF. One trial excluded patients with overt HF with unfavorable survival prognosis. One trial




Figure 1. Percentage of randomized controlled trials (n=42, except for kidney failure, n=41) excluding specific predefined groups of interest.

Partially excluded: Part of group excluded (eg, not any heart failure but only patients with specific New York Heart Association stages excluded). Clearly excluded: whole group defined as exclusion criterion. No trial specifically defined multimorbidity, polypharmacy, or non-Whites as an exclusion criterion (0.0%; not shown in the graph). #Kidney failure: n=1 trial excluded for analysis (all patients on hemodialysis). *Women: Group of childbearing potential, pregnant, or lactating women excluded. n=1 trial excluded all women; **See Table S4. COPD indicates chronic obstructive pulmonary disease; and RCTs, randomized controlled trials.

excluded patients with “symptomatic” HF or ejection fraction <35%, 1 excluded patients with “severe” HF, and 2 trials excluded patients with systolic HF. Thirty-one percent of the trials did not report whether patients with HF were excluded or included (Figure S3).

At least 1 group of immunocompromised patients (eg, patients requiring cyclosporine or other treatment with immunosuppressive agents) was excluded from 64.3% (n=27) of trials, while 26.2% (n=11) excluded all patients with serious diseases. Only the ALERT (assessment of Lescol in renal transplantation) trial did not exclude any immunocompromised patients because all patients were transplant recipients. In addition, 26.2% (n=11) of the trials did not report whether they included or excluded immunocompromised patients (Figure S3).

Patients with cancer, including subgroups (eg, history of cancer other than nonmelanoma skin cancer), were excluded in 47.6% (n=20) of trials. Also, 16.7% (n=7) of the trials did not report whether they included or excluded patients with cancer (Figure S3).

Patients with dementia were specifically excluded in 28.6% (n=12) of trials, but 50% of trials circumscribed this exclusion, for example, limiting it to patients who could provide informed consent; 47.6% (n=20) of trials did not state whether they included or excluded patients with dementia (Figure S3).

Patients ≥ 75 years of age were excluded in 28.6% (n=12) of trials; 7.1% (n=3) excluded those >70 years of age. All trials provided information on age (Figure 2).

Other Groups

Patients with atrial fibrillation, including subgroups of atrial fibrillation such as “uncontrolled,” were excluded from 19% (n=8) of trials; 50% (n=21) did not report whether they included or excluded patients with atrial fibrillation. Patients with chronic obstructive pulmonary disease were excluded from 7.1% (n=3) of trials; 83% (n=35) did not report whether they included or excluded patients with chronic obstructive pulmonary disease. Patients with mental illness were excluded from 14.3% (n=6) of trials; 26.2% excluded patients with mental illness circumscribed (eg, as a “condition that would interfere with optimal participation”); and 73.8% (n=31) of trials did not state whether they included or excluded patients with mental illness. Patients with treated thyroid disease were excluded from 2.4% (n=1) of trials. Sixty percent (n=25) of trials did not report whether they included or excluded patients with treated thyroid disease. No trial mentioned non-Whites, polypharmacy, or multimorbidity as an exclusion criterion. Because of nonreporting or selective reporting of baseline medications or baseline comorbidities, we could not assess

the inclusion or exclusion of patients with polypharmacy in 90.5% (n=38) of trials and with multimorbidity in 11.9% (n=5) of trials (Figure 1; Figure S3).

Prevalence of Specific Conditions

Pooled prevalence (average of rates) was 25% (95% CI, 0%–49%) for patients >70 years of age and 11% (95% CI, 3%–18%) for patients >75 years of age (Figure 2,^{26,31–62} Figure S4).

Pooled prevalence (average of rates) of multimorbidity was at least 51% (95% CI, 38%–63%) (Figure 3).^{15,26,32–34,36–51,53–55,57–59,61–70} Pooled prevalence (average of rates) of women was 30% (95% CI, 24%–37%). Pooled prevalence (average of rates) of non-Whites was at least 16% (95% CI, 10%–23%).

The overall rates for multimorbidity, participants >70 years of age, participants >75 years of age, women, and non-Whites were similar to the average

rates (Table S5), indicating robust results, despite high heterogeneity.

DISCUSSION

Patients with conditions such as severe renal dysfunction (creatinine clearance <30 mL/min), severe congestive HF, immunosuppressant conditions, dementia, and mental illness were often excluded in large lipid-lowering therapy (LLT) trials. No trial, even recent trials, listed multimorbidity or polypharmacy as an exclusion or inclusion criterion, with a pooled prevalence of 51% (95% CI, 38%–63%) of multimorbid patients (defined as ≥ 2 chronic diseases). One-third of the trials excluded patients >75 years of age, with a pooled prevalence of elderly patients (>75 years of age) of only 11%.

We specifically assessed the presence of chronic conditions based on data from the baseline tables and




Figure 2. Pooled prevalence of patients >75 years of age.

Trials with unknown number of patients excluded: *only data for patients ≥ 75 years of age are available. Pooled prevalence for patients >75 years of age was 11% (95% CI, 3%–18%). Except for the PROSPER,³⁸ CORONA,⁵⁴ and EWTOPIA-75⁶¹ trials, the prevalence of patients >75 years of age was <25%. Ten of 33 trials did not include patients >75 years of age. Only the EWTOPIA-75⁶¹ trial included only those >75 years of age. ES indicates effect size.




Figure 3. Pooled prevalence of multimorbid patients (≥2 chronic diseases). Trials with unknown number of patients excluded: Pooled prevalence of multimorbidity was at least 51% (95% CI, 38%–63%). The prevalence of multimorbidity varies widely among studies, with only 1 study (4D)⁴⁹ only including multimorbid patients. ES indicates effect size.

found that chronic conditions were often reported in large LLT trials. This contrasts with Jadad et al, who examined 284 trial reports from a variety of medical domains published before 2011 and found that few trials considered multiple chronic diseases.¹² Jadad et al judged the trials as “not considering chronic diseases” if specific conditions were not named through the article or terms such as comorbidities or coexisting diseases were not mentioned, but we found that the wording “comorbidities or coexisting diseases” was uncommonly used, while this study did not consider how many concomitant diseases the patients had. Using the definition of multimorbidity of being >2 chronic conditions, we found that most of the trials included patients with at least 2 chronic conditions. This proportion is probably lower than patients treated in clinical practice (up to 80% reported).⁷¹ In accordance with our results, Hanlon et al examined individual

participant data from 116 industry-sponsored trials (122 969 participants) of novel drug treatments for 22 common index conditions and assessed the same comorbidities for the same index conditions in data from a nationally representative community sample of 2.3 million people. Hanlon et al found that >30% of trial participants had ≥2 comorbidities for half of the index conditions.¹¹

For several common medical conditions, evidence on statin benefits and side effects is low, because patients with specific common conditions such as severe CKD, severe HF, dementia, and mental illness, or even groups of women were commonly excluded. It is not clear why these medical groups were excluded from these trials, and as previously published usually no reason is given for most of the exclusion criteria.⁷² In addition, in most of the excluded medical conditions lipid-lowering drugs are not contraindicated. The

reason for excluding common conditions may be to avoid situations that could limit the effectiveness of the medications tested or increase the risk of side effects. As to CKD, most of the lipid-lowering drugs are not contraindicated. The official guidelines differ for the different drugs. For example, ezetimibe does not need an adjustment in severe renal failure, whereas with most statins it is recommended to start at a low dose and to up-titrate.⁷³ Not only are most of the lipid-lowering drugs not contraindicated in CKD, but it is also essential to include this patient group in RCTs about LLT, because there is an association between decreasing eGFR and CVD risk (independent risk factor)^{74–76} but inconclusive evidence on the benefits of statins for advanced CKD.^{49,58,77,78} Because many studies excluded patients with higher-grade renal insufficiency, it is not possible to assess whether the side effects of statin therapy (eg, interactions with other drugs) or the benefits outweigh the risks. However, in the 4D (Die Deutsche Diabetes Dialyse Studie) trial comparing atorvastatin versus placebo in patients treated with hemodialysis, there was no statistically significant effect on the composite end point of cardiovascular death, myocardial infarction, and stroke.⁴⁹ It may be reasonable not to start statin therapy in multimorbid older patients requiring dialysis or in patients with severe renal insufficiency in the primary prevention,^{3,79} and perhaps it would be reasonable as well to stop statins among those patients, as it is currently explored among multimorbid older adults in primary prevention in a randomized trial.⁸⁰

Regarding chronic HF, the European Society of Cardiology guidelines do not recommend routine administration of statins in patients with HF without other indications for statin use. They do not recommend the discontinuation of statin treatment after the occurrence of HF because there is no evidence of harm.⁸¹ In contrast, Massumeh et al hypothesized in their review that high doses of statins in patients with long-term HF might lead to a progression by inhibiting coenzyme Q10 synthesis and intensifying hypertrophy.⁸² Given the exclusion of patients with moderate to severe HF in >60% of all LLT trials and the possibility of worsening HF because of statin therapy, the discontinuation of statins in HF in the primary prevention should be further studied.⁸⁰

Concerning the age of patients, international guidelines offer only cautious treatment recommendations regarding statin initiation in adults >75 years of age.¹⁹ In accordance with this, we found that the pooled prevalence of elderly patients (>75 years of age) was only 11%, whereas one-third of trials excluded older adults, suggesting we need more trials that specifically target this population.^{17,20} This is in keeping with the European Society of Cardiology guidelines on dyslipidemia prevention, which give a level of evidence IIb in treating older adults for primary prevention.^{81,83}

The European Society of Cardiology guidelines on dyslipidemia prevention mention that only the LIPID (long-term intervention with pravastatin in ischemic disease) trial has reported significant cardiovascular benefits in the subgroup of women, because women have not been adequately represented in other statin trials.^{81,84} This correlates with our findings that 71.4% of all studies excluded groups of women. The CTTC meta-analysis of 2015 found that only 27% of all participants were women and that women were generally at lower cardiovascular risk than men included in these trials.⁸⁵ The underrepresentation of women in CVD trials translates into limited knowledge of the efficacy and safety of statins in women compared with men. This is especially true because evidence suggests that women are more likely to discontinue therapies and withdrew consents in large CVD trials.⁸⁶ Furthermore, given the large proportion of female patients who have the occurrence of CVD in later age, the additional exclusion of older adults >75 or 80 years of age can only accentuate the underrepresentativeness of women in clinical trials. Compared with men, women with CVD are underdiagnosed and undertreated.^{87,88} We suggest that future trials should only exclude pregnant women or women wishing to become pregnant and that women with adequate contraception or after menopause should be included in all future lipid-lowering trials. Our findings have methodological implications for future research and clinical practice. Excluding patients with specific common medical conditions, older adults, or women could be particularly relevant in terms of adverse effects, because specific diseases or characteristics could be associated with higher prevalence of myalgia, for example.⁸⁹ An earlier retrospective study by Hervas Angulo et al determined the characteristics between participants included in large primary prevention trials of hypercholesterolemia and a population of 11 500 inhabitants of Northern Spain with hypercholesterolemia.¹⁶ They found that between 54% and 97% of participants have been excluded from these cardiovascular trials. In addition, previous studies have shown that very often the exclusion of participants from clinical trials is not sufficiently justified,^{72,90} which our study findings also support. Future trials need to minimize exclusion criteria, specifically when it comes to older adults, women, as well as patients with common medical conditions, and should proactively promote the inclusion of these groups. Considering societal aging and widespread multimorbidity, a better description of the prevalence of multimorbid and participants with polypharmacy is crucial. In addition, subgroup analyses using multivariable models on the effectiveness and possible harms of interventions in this vulnerable population are important, considering pharmacokinetic interactions but also in order to increase adherence and adoption of interventions in the wider population.⁹¹

Our study had several limitations. First, our pooled prevalence for multimorbidity (defined as >2 chronic conditions) is most likely an underestimate. We had to calculate multimorbidity by proxy, based on data from the baseline tables, and because of missing data we could not calculate multimorbidity in 11.9% of trials. Second, we could not assess polypharmacy in 90% of the trials because of missing data. Finally, we included some studies with high risk of bias. However, for the prevalence of comorbidity and of other conditions, the risk of bias is unlikely to have an impact on the results.

CONCLUSIONS

Most lipid-lowering trials excluded large groups of patients managed in clinical practice. Over half of the trials excluded patients with moderate to severe CKD, moderate to severe HF, or with an immunosuppressant condition, which could possibly lead to biased outcomes and possibly more side effects in these groups. Additionally, more than two-thirds of all studies excluded groups of women, which results in limited knowledge of the efficacy and safety of LLT in women compared with men. One-third of all studies excluded older adults, and the prevalence of patients >75 years of age over all studies was only 11%. Multimorbid patients (≥ 2 conditions) represented at least 51% of the included population. Nevertheless, no study specifically reported the inclusion or exclusion of multimorbid patients or patients with polypharmacy. Given that multimorbidity and polypharmacy are common and can contribute to adverse events in drug trials, future studies should minimize those inadequately justified exclusion criteria, promote diversity in the recruitment strategies, and improve equity in cardiovascular research to warrant a generalizable treatment effect estimation and safety for clinical practice.

ARTICLE INFORMATION

Received May 4, 2022; accepted November 2, 2022.

Affiliations

Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland (M.A., N.K., A.S., M.R.B., D.A., N.R., E.M.); Institute of Primary Health Care (BIHAM), University of Bern, Switzerland (M.A., N.K., M.R.B., C.D.G., B.G., N.R., E.M.); Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, CA (D.C.B.); and Division of Cardiology, Geneva University Hospitals, Geneva, Switzerland (B.G.).

Sources of Funding

This study was partly supported by a grant from the Swiss National Science Foundation to study the usefulness of statins among older adults in primary prevention (IICT 33IC30-193052 to N.R.). The sponsor played no role in the design, analysis, or reporting of the trial.

Disclosures

None.

Supplemental Material

Data S1
Table S1–S5
Figure S1–S4

REFERENCES

1. Organization WH. The top 10 causes of death: World Health Organization; 2020 [updated 09.12.2020; cited 2022 03.05.2022]. Available from: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>
2. Wilkins EWL, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, Burns R, Rayner M, Townsend N. *European Cardiovascular Disease Statistics 2017*. European Heart Network AISBL; 2017.
3. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, De Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation*. 2019;139:e1082–e1143.
4. Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. *BMJ Open*. 2019;9:e023085. doi: 10.1136/bmjopen-2018-023085
5. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy J, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation*. 2019;140:e596–e646. doi: 10.1161/CIR.0000000000000678
6. Redberg RF, Katz MH. Statins for primary prevention: the debate is intense, but the data are weak. *JAMA*. 2016;316:1979–1981. doi: 10.1001/jama.2016.15085
7. Liberopoulos G, Trikalinos NA, Ioannidis JP. The elderly were under-represented in osteoarthritis clinical trials. *J Clin Epidemiol*. 2009;62:1218–1223. doi: 10.1016/j.jclinepi.2008.12.009
8. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". *Lancet*. 2005;365:82–93. doi: 10.1016/S0140-6736(04)17670-8
9. Ruokoniemi P, Sund R, Arffman M, Helin-Salmivaara A, Huupponen R, Keskimäki I, Vehko T, Korhonen MJ. Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. *BMJ Open*. 2014;4:e005402. doi: 10.1136/bmjopen-2014-005402
10. Averitt AJ, Weng C, Ryan P, Perotte A. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. *NPJ Digit Med*. 2020;3:67. doi: 10.1038/s41746-020-0277-8
11. Hanlon P, Hannigan L, Rodriguez-Perez J, Fischbacher C, Welton NJ, Dias S, Mair FS, Guthrie B, Wild S, McAllister DA. Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis. *BMC Med*. 2019;17:201. doi: 10.1186/s12916-019-1427-1
12. Jadad AR, To MJ, Emara M, Jones J. Consideration of multiple chronic diseases in randomized controlled trials. *JAMA*. 2011;306:2670–2672. doi: 10.1001/jama.2011.1886
13. Buffel du Vaure C, Dechartres A, Battin C, Ravaut P, Boutron I. Exclusion of patients with concomitant chronic conditions in ongoing randomised controlled trials targeting 10 common chronic conditions and registered at ClinicalTrials.gov: a systematic review of registration details. *BMJ Open*. 2016;6:e012265. doi: 10.1136/bmjopen-2016-012265
14. Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY, Geller RJ, Elahi M, Temple RJ, Woodcock J. Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. *J Am Coll Cardiol*. 2018;71:1960–1969. doi: 10.1016/j.jacc.2018.02.070
15. Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM; the TRACE RA Consortium, Kitas G, Belch J, Symmons D, et al. A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. *Arthritis Rheumatol*. 2019;71:1437–1449. doi: 10.1002/art.40892
16. Hervas Angulo A, Lacosta Ramirez U, Brugarolas Brufau C, Diez Espino J. Validity in a community (with outside verification) of primary prevention studies on hypercholesterolemia. *Aten Primaria*. 2003;32:509–513.

17. Singh S, Ziemann S, Go AS, Fortmann SP, Wenger NK, Fleg JL, Radziszewska B, Stone NJ, Zoungas S, Gurwitz JH. Statins for primary prevention in older adults—moving toward evidence-based decision-making. *J Am Geriatr Soc.* 2018;66:2188–2196. doi: 10.1111/jgs.15449
18. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *J Am Coll Cardiol.* 2019;73:e285–e350. doi: 10.1016/j.jacc.2018.11.003
19. van der Ploeg MA, Floriani C, Achterberg WP, Bogaerts JMK, Gusselklo J, Mooijaart SP, Streit S, Poortvliet RK, Drewes YM. Recommendations for (dis)continuation of statin treatment in older adults: review of guidelines. *J Am Geriatr Soc.* 2020;68:417–425. doi: 10.1111/jgs.16219
20. Foody JM, Rathore SS, Galusha D, Masoudi FA, Havranek EP, Radford MJ, Krumholz HM. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. *J Am Geriatr Soc.* 2006;54:421–430. doi: 10.1111/j.1532-5415.2005.00635.x
21. Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet.* 2019;393:407–415. doi: 10.1016/S0140-6736(18)31942-1
22. Mansfield KE, Sim J, Jordan JL, Jordan KP. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. *Pain.* 2016;157:55–64. doi: 10.1097/j.pain.0000000000000314
23. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* 2015;4:1. doi: 10.1186/2046-4053-4-1
24. Cholesterol Treatment Trialists C. CTTC [updated May 2021; cited 2022 31.01]. Available at: <https://www.cttcollaboration.org/>
25. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM. Efficacy and safety of alirociclib in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. *Eur Heart J.* 2015;36:1186–1194.
26. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med.* 2015;372:2387–2397. doi: 10.1056/NEJMoa1410489
27. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ.* 2019;366:l4898.
28. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. *J Epidemiol Community Health.* 2013;67:974–978.
29. Munn ZMS, Lisy K, Riitano D, Tufanaru C. *Chapter 5: Systematic Reviews of Prevalence and Incidence JBI, 2017.* Joanna Briggs Institute; 2017. Available at: <https://synthesismanual.jbi.global>.
30. Hansen S, Rice K. Exact inference for fixed-effects meta-analysis of proportions. *Res Synth Methods.* 2022;13:204–213. doi: 10.1002/jrsm.1526
31. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, JH MK, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. *N Engl J Med.* 1995;333:1301–1307.
32. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). *Lancet.* 1994;344:1383–1389.
33. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. *N Engl J Med.* 1996;335:1001–1009. doi: 10.1056/NEJM199610033351401
34. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. *N Engl J Med.* 1997;336:153–162. doi: 10.1056/NEJM199701163360301
35. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol Levels Results of AFCAPS/TexCAPS. *JAMA.* 1998;279:1615–1622. doi: 10.1001/jama.279.20.1615
36. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med.* 1998;339:1349–1357. doi: 10.1056/NEJM199811053391902
37. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione investigators (Gruppo Italiano per lo studio della Sopravvivenza nell'Infarto Miocardico). *Ital Heart J.* 2000;1:810–820.
38. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet.* 2002;360:1623–1630.
39. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. *Lancet.* 2002;360:7–22. doi: 10.1016/S0140-6736(02)09327-3
40. Major outcomes in moderately hypercholesterolemic. Hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). *JAMA.* 2002;288:2998–3007.
41. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek atorvastatin and coronary-heart-disease evaluation (GREECE) study. *Curr Med Res Opin.* 2002;18:220–228.
42. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *JAMA.* 2002;287:3215–3222. doi: 10.1001/jama.287.24.3215
43. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes G, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet.* 2003;361:1149–1158. doi: 10.1016/S0140-6736(03)12948-0
44. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet.* 2003;361:2024–2031. doi: 10.1016/S0140-6736(03)13638-0
45. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. *Lancet.* 2004;364:685–696. doi: 10.1016/S0140-6736(04)16895-5
46. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA.* 2004;292:1307–1316. doi: 10.1001/jama.292.11.1307
47. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med.* 2004;350:1495–1504. doi: 10.1056/NEJMoa040583
48. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. *J Am Coll Cardiol.* 2004;44:1772–1779.
49. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med.* 2005;353:238–248. doi: 10.1056/NEJMoa043545
50. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendixsen FS, Lindahl C, Szarek M, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA.* 2005;294:2437–2445.

51. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJ, Shepherd J, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*. 2005;352:1425–1435. doi: 10.1056/NEJMoa050461
52. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. *Lancet*. 2006;368:1155–1163. doi: 10.1016/S0140-6736(06)69472-5
53. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). *Diabetes Care*. 2006;29:1478–1485. doi: 10.2337/dc05-2415
54. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, et al. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med*. 2007;357:2248–2261. doi: 10.1056/NEJMoa0706201
55. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerds E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med*. 2008;359:1343–1356. doi: 10.1056/NEJMoa0804602
56. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, JG MF, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195–2207.
57. Tavazzi L, Maggioni AP, Marchioni R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2008;372:1231–1239. doi: 10.1016/S0140-6736(08)61240-4
58. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med*. 2009;360:1395–1407. doi: 10.1056/NEJMoa0810177
59. Study of the Effectiveness of Additional Reductions in C, Homocysteine Collaborative G. Intensive lowering of LDL cholesterol with 80mg versus 20mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet*. 2010;376:1658–1669. doi: 10.1016/S0140-6736(10)60310-8
60. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med*. 2016;374:2021–2031. doi: 10.1056/NEJMoa1600176
61. Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, Urabe T, Uchida Y, Hayashi M, Yokota N, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75). *Circulation*. 2019;140:992–1003. doi: 10.1161/CIRCULATIONAHA.118.039415
62. Amarencu P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, et al. A comparison of two LDL cholesterol targets after ischemic stroke. *N Engl J Med*. 2019;382:9–19. doi: 10.1056/NEJMoa1910355
63. Amarencu P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, Sillensen H, Simunovic L, Szarek M, Welch KM, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med*. 2006;355:549–559. doi: 10.1056/NEJMoa061894
64. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Crane V, Cass A, Craig J, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. *Lancet*. 2011;377:2181–2192. doi: 10.1016/S0140-6736(11)60739-3
65. Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, Maruyama H, Sunami N, Yokota C, Kitagawa K, et al. The Japan statin treatment against recurrent stroke (J-STARS): a multicenter, randomized, open-label, Parallel-group Study. *EBioMedicine*. 2015;2:1071–1078. doi: 10.1016/j.ebiom.2015.08.006
66. Hagiwara N, Kawada-Watanabe E, Koyanagi R, Arashi H, Yamaguchi J, Nakao K, Tobaru T, Tanaka H, Oka T, Endoh Y, et al. Low-density lipoprotein cholesterol targeting with pitavastatin+ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. *Eur Heart J*. 2017;38:2264–2276.
67. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*. 2017;376:1713–1722. doi: 10.1056/NEJMoa1615664
68. Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, et al. Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: report of a randomized study. *Diabetes Care*. 2018;41:1275–1284. doi: 10.2337/dc17-2224
69. Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, et al. High-dose versus low-dose Pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. *Circulation*. 2018;137:1997–2009. doi: 10.1161/CIRCULATIONAHA.117.032615
70. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med*. 2018;379:2097–2107. doi: 10.1056/NEJMoa1801174
71. Aubert CE, Fankhauser N, Marques-Vidal P, Stirnemann J, Aujesky D, Limacher A, Donzé J. Patterns of multimorbidity in internal medicine patients in Swiss university hospitals: a multicentre cohort study. *Swiss Med Wkly*. 2019;149:w20094.
72. Schmidt AF, Groenwold RH, van Delden JJ, van der Does Y, Klungel OH, Roes KC, Hoes AW, Van Der Graaf R. Justification of exclusion criteria was underreported in a review of cardiovascular trials. *J Clin Epidemiol*. 2014;67:635–644. doi: 10.1016/j.jclinepi.2013.12.005
73. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, de Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS). *Eur Heart J*. 2019;41:111–188. doi: 10.1093/eurheartj/ehz455
74. Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J. The risk of atherosclerosis in patients with chronic kidney disease. *Int Urol Nephrol*. 2013;45:1605–1612. doi: 10.1007/s12555-013-0407-1
75. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet*. 2013;382:339–352.
76. Franczyk-Skóra B, Gluba A, Banach M, Rozenytr P, Polorński L, Rysz J. Acute coronary syndromes in patients with chronic kidney disease. *Curr Vasc Pharmacol*. 2013;11:758–767. doi: 10.2174/157016111311050013
77. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. *Ann Intern Med*. 2012;157:263–275. doi: 10.7326/0003-4819-157-4-201208210-00007
78. Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. *Eur Heart J*. 2013;34:1807–1817. doi: 10.1093/eurheartj/ehz065
79. Sharp Collaborative G. Study of heart and renal protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9438 patients with chronic kidney disease. *Am Heart J*. 2010;160:785–94.e10. doi: 10.1016/j.ahj.2010.08.012
80. Statins in Multimorbid Older Adults Without Cardiovascular Disease (STREAM) [cited 2022 26.07]. Available at: <https://www.statin-stream.ch/>.
81. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, de Backer GG, Delgado V, Ference BA, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455
82. Niazi M, Galehdar N, Jamshidi M, Mohammadi R, Moayyedkazemi A. A review of the role of statins in heart failure treatment. *Curr Clin Pharmacol*. 2020;15:30–37. doi: 10.2174/1574884714666190802125627
83. Rea F, Biffi A, Ronco R, Franchi M, Cammarota S, Citarella A, Conti V, Filippelli A, Sellitto C, Corrao G. Cardiovascular outcomes and mortality associated with discontinuing statins in older patients receiving polypharmacy. *JAMA Netw Open*. 2021;4:e2113186. doi: 10.1001/jamanetworkopen.2021.13186

-
84. Hague W, Forder P, Simes J, Hunt D, Tonkin A. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the long-term intervention with pravastatin in ischemic disease (LIPID) study. *Am Heart J*. 2003;145:643–651. doi: [10.1067/mhj.2003.1](https://doi.org/10.1067/mhj.2003.1)
 85. Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. *Lancet*. 2015;385:1397–1405. doi: [10.1016/S0140-6736\(14\)61368-4](https://doi.org/10.1016/S0140-6736(14)61368-4)
 86. Lau ES, Braunwald E, Morrow DA, Giugliano RP, Antman EM, Gibson CM, Scirica BM, Bohula EA, Wiviott SD, Bhatt DL, et al. Sex, permanent drug discontinuation, and study retention in clinical trials. *Circulation*. 2021;143:685–695.
 87. ESC. Cardiovascular Disease in Women Reducing the gender gap in prevention, diagnosis and treatment of cardiovascular disease [cited 2022 19.07.22]. Available at: <https://www.escardio.org/The-ESC/Advocacy/women-and-cardiovascular-disease>
 88. *Heart Attack Diagnosis Missed in Women more Often than in Men*. ESC-European Society of Cardiology. [press release]. <https://www.escardio.org/The-ESC/Press-Office/Press-releases/Heart-attack-diagnosis-missed-in-women-more-often-than-in-men>. Accessed 12 Mar, 2021
 89. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. *Stroke*. 2002;40:567–572.
 90. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. *JAMA*. 2007;297:1233–1240. doi: [10.1001/jama.297.11.1233](https://doi.org/10.1001/jama.297.11.1233)
 91. van Klaveren D, Varadhan R, Kent DM. The predictive approaches to treatment effect heterogeneity (PATH) statement. *Ann Intern Med*. 2020;172:776.

Supplemental Material

Supplemental Methods

Data S1. Search strategy.

Date last search **25 May 2021**

	Before deduplication	After deduplication
MEDLINE (Ovid)	1134	1131
EMBASE (Ovid)	2560	1678
Cochrane CENTRAL	2102	648
Total	5796	3457

2339 duplicate records were removed

Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions(R) <1946 to May 24, 2021>

```
1      exp cholesterol/
2      (cholesterol* or lipid* or LDL).ab,ti,kf.
3      1 or 2
4      exp Anticholesteremic Agents/
5      ((inhibit* adj3 ("hmg-coa*" or "Hydroxymethylglutaryl CoA*" or "Hydroxymethylglutaryl-Coenzyme A")) or statins or statin
or simvastatin or rosuvastatin or pravastatin or pitavastatin or mevastatin or lovastatin or glenvastatin or fluvastatin or
fluidostatin or dalvastatin or crilvastatin or atorvastatin or cerivastatin or bervastatin or medostatin).ab,kf,ti,nm.
6      (altoprev or altoacor or baycol or canef or cranoc or compactin or crestor or lescol or lipitor or lipex or lipostat or livalo or
local or lochol or mevinolin or mevacor or mevalotin or mevinacor or monacolin or pravachol or pitava or pravachol or pravasin
or zocor).mp.
7      (antichol* or antihyperchol* or hypochole* or hypolipidemic* or antihyperlipidemic* or anti-hyperlipidemic* or Ezetimibe or
PCSK9 inhibitor* or Alirocumab or evolocumab or non-statin*).ab,ti,kf.
8      4 or 5 or 6 or 7
9      exp cardiovascular diseases/ or exp mortality/
10     (((cardiovascular or heart or coronar* or cardiac) adj3 (disease* or event* or attack* or mortalit* or death* or arrest*)) or
cvd or cvds or CV-mortalit* or MACE or angina or ((heart or cardia* or myocard*) adj3 (ischemi* or ischaemi* or fail* or
insufficien*)) or ((myocard* or heart or cardiac) adj3 (infarct* or attack*)) or (cerebrovascular* adj3 (accident* or event*)) or cva
or stroke* or ((brain or cerebral) adj3 (ischemi* or ischaemi*))).ti,ab.
11     9 or 10
12     3 and 8 and 11
13     randomized controlled trial.pt.
14     (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.
15     (retraction of publication or retracted publication).pt.
16     or/13-15
17     (animals not humans).sh.
18     ((comment or editorial or meta-analysis or practice-guideline or review or letter) not randomized controlled trial).pt.
4822254
19     (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not randomized
controlled trial.pt
20     16 not (17 or 18 or 19)
21     12 and 20
22     limit 21 to yr="2015 -Current"
```

mp=(multi-purpose field): title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, author keyword heading word, organism supplementary concept word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms

nm=Name of substance word

kf=Author keyword heading word

BMJ Best Practice Study design search filters
Medline randomised controlled trial strategy
<https://bestpractice.bmj.com/info/toolkit/learn-ebm/study-design-search-filters/>

Embase (Ovid) <1974 to 2021 May 24>

```
1 cholesterol/
2 (cholesterol* or lipid* or LDL).ti,ab,kw.
3 1 or 2
4 exp hypocholesterolemic agent/
5 ((inhibit* adj3 ("hmg-coa*" or "Hydroxymethylglutaryl CoA*" or "Hydroxymethylglutaryl-Coenzyme A")) or statins or statin
or simvastatin or rosuvastatin or pravastatin or pitavastatin or mevastatin or lovastatin or glenvastatin or fluvastatin or
flundostatin or dalvastatin or crilvastatin or atorvastatin or cerivastatin or cerivastatin or bervastatin or medostatin).ab,kw,ti,rn.
6 (altoprev or altocor or baycol or canef or cranoc or compactin or crestor or lescol or lipitor or lipex or lipostat or livalo or
locol or lochol or mevinolin or mevacor or mevalotin or mevinacor or monacolin or pravachol or pitava or pravachol or pravasin
or zocor).mp.
7 (antichol* or antihyperchol* or hypocho* or hypolipidemic* or antihyperlipidemic* or anti-hyperlipidemic* or Ezetimibe or
PCSK9 inhibitor* or Alirocumab or evolocumab or non-statin*).ti,ab,kw.
8 4 or 5 or 6 or 7
9 exp cardiovascular disease/ or exp mortality/
10 (((cardiovascular or heart or coronar* or cardiac) adj3 (disease* or event* or attack* or mortalit* or death* or arrest*)) or
cvd or cvds or CV-mortalit* or MACE or angina or ((heart or cardia* or myocard*) adj3 (ischemi* or ischaemi* or fail* or
insufficien*)) or ((myocard* or heart or cardiac) adj3 (infarct* or attack*)) or (cerebrovascular* adj3 (accident* or event*)) or cva
or stroke* or ((brain or cerebral) adj3 (ischemi* or ischaemi*))).ti,ab.
11 9 or 10
12 3 and 8 and 11
13 (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab.
14 RETRACTED ARTICLE/
15 13 or 14
16 (animal$ not human$).sh,hw.
17 (book or conference paper or editorial or letter or review).pt. not exp randomized controlled trial/
18 (random sampl$ or random digit$ or random effect$ or random survey or random regression).ti,ab. not exp randomized
controlled trial/
19 15 not (16 or 17 or 18)
20 12 and 19
21 limit 20 to yr="2015 -Current"
```

mp=(multi-purpose field) title, abstract, heading word, drug trade name, original title, drug manufacturer, author keyword,
floating subheading word, candidate term word

rn=CAS Registry Number (chemical names)

kw=Author keyword

BMJ Best Practice Study design search filters
Embase randomised controlled trial strategy
<https://bestpractice.bmj.com/info/toolkit/learn-ebm/study-design-search-filters/>

Cochrane CENTRAL

Cochrane Central Register of Controlled Trials

```
#1 (cholesterol* or lipid* or LDL):ti,ab,kw
#2 (statin or statins or (inhibit* NEAR/3 ("hmg coa" or "Hydroxymethylglutaryl CoA" or "Hydroxymethylglutaryl Coenzyme"))
or atorvastatin or cerivastatin or crilvastatin or dalvastatin or flundostatin or fluvastatin or glenvastatin or lovastatin or mevastatin
or pitavastatin or pravastatin or rosuvastatin or simvastatin)
#3 (altoprev or altocor or baycol or canef or cranoc or compactin or crestor or lescol or lipitor or lipex or lipostat or livalo or
locol or lochol or mevinolin or mevacor or mevalotin or mevinacor or monacolin or pravachol or pitava or pravachol or pravasin
or zocor)
#4 (antichol* or antihyperchol* or hypocho* or hypolipidemic* or antihyperlipidemic* or anti-hyperlipidemic* or Ezetimibe or
PCSK9 inhibitor* or Alirocumab or evolocumab or (non NEXT statin*))
#5 #2 or #3 or #4
#6 (((cardiovascular or heart or coronar* or cardiac) NEAR/3 (disease* or event* or attack* or mortalit* or death* or arrest*))
or cvd or cvds or CV-mortalit* or MACE or angina or ((heart or cardia* or myocard*) NEAR/3 (ischemi* or ischaemi* or fail* or
insufficien*)) or ((myocard* or heart or cardiac) NEAR/3 (infarct* or attack*)) or (cerebrovascular* NEAR/3 (accident* or event*))
or cva or stroke* or ((brain or cerebral) NEAR/3 (ischemi* or ischaemi*)))
#7 #1 AND #5 AND #6
#8 Filter year range: 2015 to 2021
```


Table S1: Abbreviations of study titles

Abbreviations	Study title
SSSS (4S)	The Scandinavian Simvastatin Survival Study <i>Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study</i>
WOSCOPS	The West of Scotland Coronary Prevention Study <i>Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia</i>
CARE	The Cholesterol and Recurrent Events Trial <i>The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels</i>
AFCAPS/TexCaps	Air Force Texas Coronary Atherosclerosis Prevention Study <i>Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels</i>
LIPID	The Long-Term Intervention with Pravastatin in Ischaemic Disease Study <i>Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels</i>
GISSI-P	Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico Prevenzione trial <i>Results of the low-dose (20mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?</i>
HPS	The Heart Protection Study <i>Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial</i>
LIPS	The Lescol Intervention Prevention Study

Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention

The PROspective Study of Pravastatin in the Elderly at Risk

PROSPER

Pravastatin in elderly individuals at risk of vascular disease: a randomised controlled trial

Assessment of LEscol in Renal Transplantation Study

ALERT

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicenter, randomized, placebo-controlled trial

The Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm

ASCOT-LLA

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm: a multicenter randomised controlled trial

Die Deutsche Diabetes Dialyse Studie

4D

Atorvastatin in Patients with Type 2 Diabetes Mellitus undergoing hemodialysis

Collaborative Atorvastatin Diabetes Study

CARDS

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study: multicenter randomised placebo-controlled trial

The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in

ASPEN

Non-Insulin-Dependent Diabetes Mellitus

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects with Type 2 Diabetes

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial

SPARCL

High-Dose Atorvastatin after Stroke or Transient Ischemic Attack

Controlled Rosuvastatin multinational study in heart failure

CORONA

Rosuvastatin in Older Patients with Systolic Heart Failure

GISSI-HF

Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca trial

	<i>Effect of Rosuvastatin in patients with chronic heart failure: a randomised, double-blind, placebo-controlled trial</i>
JUPITER	Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin <i>Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive Protein</i>
AURORA	A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: <i>An Assessment of Survival and Cardiovascular Events</i> <i>Rosuvastatin and Cardiovascular Events in patients undergoing hemodialysis</i>
HOPE-3	Heart Outcomes Prevention Evaluation-3 trial <i>Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease</i>
SHARP	Study of Heart and Renal Protection <i>The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease: a randomised placebo-controlled trial</i>
SEAS	The Simvastatin and Ezetimibe in Aortic Stenosis trial <i>Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis</i>
IMPROVE-IT	Improved Reduction of Outcomes: Vytorin Efficacy International Trial <i>Ezetimibe added to statin therapy after acute coronary syndromes</i>
FOURIER	Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk trial <i>Evolocumab and Clinical outcomes in Patients with cardiovascular disease</i>
Odyssey outcomes	Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab trial <i>Alirocumab and Cardiovascular Outcomes after acute coronary syndrome</i>
J-STARS	The Japan Statin Treatment Against Recurrent Stroke Study <i>The Japan Statin Treatment Against Recurrent Stroke: A multicenter, randomized, open-label, parallel-group study</i>
ALLIANCE	The Aggressive Lipid-Lowering Initiation Abates New Cardiac Events study

	<i>Clinical Outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The Alliance study</i>
MEGA	The Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study <i>Primary Prevention of cardiovascular disease with pravastatin in Japan: a prospective randomised controlled trial</i>
EWTOPIA 75	Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older
ALLHAT-LLT	Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial <i>Major outcomes in moderately Hypercholesterolemic, Hypertensive Patients Randomized to Pravastatin vs Usual Care</i>
GREACE	The Greek Atorvastatin and Coronary Heart Disease Evaluation Study <i>Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus "Usual" Care in Secondary Coronary Heart Disease Prevention</i>
EMPATHY	The standard versus intensive statin therapy for hypercholesterolemic Patients with diabetic retinopathy study <i>Intensive Treat-to-Target Statin Therapy in High-Risk Japanese patients with Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study</i>
PROVE-IT	The Pravastatin or Atorvastatin Evaluation and Infection Therapy trial <i>Intensive versus moderate lipid lowering with statins after acute coronary syndromes</i>
Post CABG	The post coronary artery bypass graft trial <i>The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts</i> Treating to New Targets Study
TNT	<i>Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease</i>
IDEAL	The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study

	<i>High-dose Atorvastatin vs usual-dose Simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial</i>
SEARCH	Study of the effectiveness of additional reductions in cholesterol and homocysteine <i>Intensive lowering of LDL cholesterol with 80mg versus 20mg simvastatin daily in 12064 survivors of myocardial infarction: a double-blind randomised trial</i>
A to Z	Aggrastat to Zocor trial <i>Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes</i>
TST	Treat stroke to target trial <i>A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke</i>
HIJ-PROPER	Heart Institute of Japan-PROper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome <i>Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial</i>
REAL-CAD	Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease <i>High-Dose versus Low-Dose Pitavastatin in Japanese Patients with stable coronary artery disease</i>
TRACE RA	TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis <i>A Multicenter, randomized, placebo-controlled trial of Atorvastatin for the primary prevention of cardiovascular events in patients with Rheumatoid Arthritis</i>

CARDS	Incl	Excl	Incl	Unknown	Incl	Incl	Probably	Probably	Partially	Excl	Incl	Excl	Excl	Unknown	Unknown	Probably
PROVE-IT	Incl	Incl	Incl	Unknown	Incl	Incl	Unknown	Probably	Unknown	Partially	Unknown	Excl	Partially	Unknown	Unknown	Unknown
4D	Incl	Incl	Incl	Unknown	Partially	Unknown	Unknown	Probably	Partially	Probably	Incl	n.a.	n.a.	Unknown	Unknown	Unknown
IDEAL	Incl	Incl	Incl	Unknown	Partially	Incl	Probably	Probably	Partially	Excl	Incl	Partially	Partially	Unknown	Unknown	Incl
TNT	Incl	Excl	Incl	Unknown	Partially	Incl	Unknown	Excl	Partially	Excl	Incl	Partially	Partially	Unknown	Unknown	Incl
ASPEN	Incl	Excl	Incl	Incl	Partially	Incl	Unknown	Unknown	Partially	Excl	Unknown	Excl	Probably	Unknown	Unknown	Incl
MEGA	Excl	Excl	Unknown	Unknown	Partially	Incl	Unknown	Excl	Unknown	Partially	Unknown	Partially	Partially	Unknown	Unknown	Excl
SPARCL	Incl	Incl	Incl	Unknown	Partially	Incl	Excl	Unknown	Unknown	Excl	Unknown	Excl	Probably	Unknown	Excl	Excl
CORONA	Incl	Incl	Incl	Unknown	Incl	Unknown	Unknown	Excl	Partially	Partially	Incl	Excl	Partially	Unknown	Unknown	Incl
GISSI-HF	Incl	Incl	Incl	Unknown	Partially	Unknown	Unknown	Probably	Incl	Unknown	Unknown	Excl	Partially	Incl	Unknown	Incl
JUPITER	Incl	Incl	Unknown	Unknown	Partially	Incl	Probably	Excl	Unknown	Excl	Incl	Excl	Partially	Unknown	Unknown	Unknown
AURORA	Incl	Incl	Incl	Unknown	Incl	Incl	Unknown	Excl	Unknown	Partially	Incl	Incl	Incl	Unknown	Unknown	Unknown
SEARCH	Incl	Incl	Incl	Unknown	Partially	Unknown	Probably	Probably	Unknown	Partially	Unknown	Excl	Partially	Unknown	Unknown	Unknown
J-STARS	Incl	Incl	Incl	Unknown	Incl	Incl	Incl	Excl	Unknown	Unknown	Unknown	Excl	Partially	Unknown	Unknown	Unknown
HOPE-3	Incl	Incl	Unknown	Unknown	Partially	Incl	Probably	Probably	Unknown	Partially	Unknown	Excl	Excl	Unknown	Unknown	Unknown
REAL-CAD	Incl	Incl	Incl	Unknown	Partially	Incl	Probably	Excl	Partially	Partially	Unknown	Incl	Incl	Unknown	Unknown	Incl
EMPATHY	Incl	Incl	Incl	Unknown	Partially	Incl	Unknown	Excl	Partially	Unknown	Unknown	Excl	Partially	Unknown	Unknown	Unknown
TRACE RA	Incl	Incl	Incl	Unknown	Partially	Incl	Probably	Probably	Partially	Partially	Incl	Excl	Excl	Unknown	Unknown	Probably
TST	Incl	Incl	Incl	Unknown	Partially	Incl	Unknown	Excl	Unknown	Partially	Unknown	Unknown	Unknown	Unknown	Unknown	Incl
SEAS	Incl	Incl	Incl	Unknown	Incl	Incl	Unknown	Incl	Partially	Unknown	Incl	Excl	Partially	Incl	Unknown	Incl
SHARP	Incl	Incl	Incl	Unknown	Partially	Incl	Unknown	Excl	Unknown	Partially	Unknown	Incl	Incl	Partially	Unknown	Unknown

IMPROVE-IT	Incl	Incl	Incl	Incl	Partially	Incl	Unknown	Unknown	Partially	Partially	Unknown	Excl	Partially	Unknown	Unknown	Incl
HIJ-PROPER	Incl	Incl	Incl	Unknown	Partially	Incl	Probably	Excl	Partially	Excl	Unknown	Excl	Partially	Unknown	Unknown	Incl
EWTOPIA-75	Incl	Incl	Incl	Unknown	Incl	Incl	Excl	Excl	Unknown	Unknown	Excl	Excl	Partially	Incl	Probably	Excl
FOURIER	Incl	Incl	Incl	Unknown	Partially	Incl	Excl	Excl	Partially	Excl	Incl	Partially	Partially	Unknown	Unknown	Incl
ODYSSEY OUTCOMES	Incl	Incl	Incl	Incl	Partially	Incl	Unknown	Unknown	Partially	Unknown	Unknown	Excl	Partially	Unknown	Unknown	Unknown

Excl: Patient group as a clearly defined exclusion criterion. Partially: Part of patients' group excluded (e.g. only patients with heart failure NYHA III-IV excluded). Probably: Patients' group not clearly mentioned; medical condition circumscribed. Unknown: Unknown (no information available; mentioned neither as an inclusion nor as an exclusion criterion, no information in baseline table). n.a.: Kidney failure#: n=1 trial excluded for analysis (all patients on hemodialysis)

Table S3: Baseline characteristics of the included trials

Control arm: Placebo or no treatment								
Study Name	Prevention type	Intervention	Mean age (y)	Men (prevalence %)	Follow-up (y)	Overall N	Overall LLT	Overall Control
4S	Secondary	20mg Simvastatin	58.9	81.4	5.4	4444	2221	2223
WOSCOPS	Primary	40mg Pravastatin	55.2	100	4.9	6595	3302	3293
CARE	Secondary	40mg Pravastatin	59	86	5	4159	2081	2078
AFCAPS/TexCaps	Primary	20-40mg Lovastatin	58	85	5.2	6605	3304	3301

LIPID	Secondary	40mg Pravastatin	62	83	6.1	9014	4512	4502
GISSI-P	Secondary	20mg Pravastatin	59.9	86.3	1.92	4271	2138	2133
HPS	Primary & Secondary	40mg Simvastatin	NR	75.3	5	20536	10269	10267
LIPS	Secondary	80mg Fluvastatin	60	83.8	3.9	1677	844	833
PROSPER	Primary & Secondary	40mg Pravastatin	75.3	48.3	3.2	5804	2891	2913
ALERT	Primary & Secondary	40mg Fluvastatin	49.8	66	5.1	2102	1050	1052
ASCOT-LLA	Primary & Secondary	10mg Atorvastatin	63.1	81.2	3.3	10305	5168	5137
4D	Primary & Secondary	20mg Atorvastatin	65.7	54	3.93	1255	619	636

CARDS	Primary	10mg Atorvastatin	61.7	68	3.9	2838	1428	1410
ASPEN	Primary & Secondary	10mg Atorvastatin	61.1	66.3	4	2410	1211	1199
SPARCL	Secondary	80mg Atorvastatin	62.8	59.7	4.9	4731	2365	2366
CORONA	Secondary	10mg Rosuvastatin	73	76	2.7	5011	2514	2497
GISSI-HF	Primary & Secondary	10mg Rosuvastatin	68	77.4	3.9	4574	2285	2289
JUPITER	Primary	20mg Rosuvastatin	66 (median)	61.8	1.9	17802	8901	8901
AURORA	Primary & Secondary	10mg Rosuvastatin	64.2	62.1	3.2	2773	1389	1384
HOPE-3	Primary	10mg Rosuvastatin	65.7	53.8	5.6	12705	6361	6344

SHARP	Primary	20mg Simvastatin + 10mg Ezetimibe	62	62.6	4.9	9270	4650	4620
SEAS	Primary	40mg Simvastatin + 10mg Ezetimibe	67.6	61.4	4.35	1873	944	929
IMPROVE-IT	Secondary	40mg Simvastatin + 10mg Ezetimibe	63.6	75.7	6	18144	9067	9077
FOURIER	Secondary	Evolocumab 140mg or 420mg	62.5	75.4	2.2	27564	13784	13780
Odyssey outcomes	Secondary	Alirocumab 75mg	58.6	74.8	2.8	18924	9462	9462
J-STARS	Secondary	10mg Pravastatin	66.2	68.8	4.9	1578	793	785
TRACE RA	Primary	40mg Atorvastatin	61	25.8	2.51	3002	1504	1498

Active Control or Usual care

Study Name	Prevention type	Intervention	Control	Mean age (y)	Men prevalence (%)	Follow-up (y)	Overall N	Overall LLT	Overall Control
ALLIANCE	Secondary	10-80mg Atorvastatin	Usual care	61.2	82.2	4.3	2442	1217	1225
MEGA	Primary	10-20mg Pravastatin	Diet (pyhsician could prescribe mild hypo-lipidemic drugs)	58.3	31.6	5.3	7832	3866	3966
EWTOPIA 75	Primary	10mg Ezetimibe	Usual care	80.6	25.6	4.1	3411	1716	1695
ALLHAT-LLT	Primary & Secondary	40mg Pravastatin	Usual care	66.4	51.2	4.8	10355	5170	5185
GREACE	Secondary	10-80mg Atorvastatin	Usual care	58.5	78.5	3	1600	800	800

EMPATHY	Primary	LDL-goal <70mg/dl (statin)	LDL goal 100- 120mg/dl (statin)	63.1	47.7	3.1	5042	2518	2524
PROVE-IT	Secondary	80mg Atorvastatin	40mg (-80mg) Pravastatin	58.2	78	2	4162	2099	2063
Post CABG	Secondary	40mg Lovastatin +/- Cholestyramine	2.5mg Lovastatin +/- Cholestyramine	61.5	92	4.3	1351	676	675
TNT	Secondary	80mg Atorvastatin	10mg Atorvastatin	61	81	4.9	10001	4995	5006
IDEAL	Secondary	80mg Atorvastatin	20mg Simvastatin	61.7	80.9	4.8	8888	4439	4449
SEARCH	Secondary	80mg Simvastatin	20mg Simvastatin	64.2	83	6.7	12064	6031	6033

A to Z	Secondary	40 mg Simvastatin for 1 month followed by 80mg thereafter	Placebo for 4 months followed by 20 mg Simvastatin	61 (median)	75.5	1.97	4497	2265	2232
TST	Secondary	LDL <70mg/dl	LDL 90-110mg/dl	66.7	67.6	3.5	2860	1430	1430
HIJ-PROPER	Secondary	Standard-dose Pitavastatin plus ezetimibe (LDL target <70mg/dl)	Pitavastatin (LDL target 90-100mg/dl)	65.6	75.5	3.86	1721	864	857
REAL-CAD	Secondary	4mg Pitavastatin	1mg Pitavastatin	68.1	82.6	3.9	12413	6199	6214

|

Table S4: Exclusion criteria HF

Exclusion criterion HF	Trials (n)
HF treated with digitalis, diuretics, vasodilators	1
HF treated with digoxin	1
NYHA II-IV	2
NYHA III-IV	7
NYHA III-IV or EF<30%	2
NYHA III-IV persisting despite treatment or EF <25%	1
EF <30%	3
EF <25%	1
Symptomatic HF or EF <35%	1
Severe HF	1
Systolic HF	2
Overt HF (unfavorable survival prognosis)	1
Congestive HF within last 3 months	1
Decompensated congestive HF or need for inotropic therapy (digitalis allowed)	1
Decompensated congestive HF 24h prior to screening	1
Hemodynamic instability 24h before enrolment	1

Table S5: Pooled prevalence - comparison overall and average rates

	Prevalence of Multimorbidity in % (95% CI)	Prevalence of participants >75years in % (95% CI)	Prevalence of participants >70 years in % (95% CI)	Prevalence of women in % (95% CI)	Prevalence of non-whites in % (95% CI)
Average rates	51 (38-63)	11 (3-18)	25 (0-49)	30 (24-37)	16 (10-23)
Overall rates	52.5 (52.3-52.7)	10 (9.9-10.2)	24 (24.0-24.4)	29(28.7-29.0)	21 (20.8-21.2)

*Average rate is calculated from meta-analysis based on the Freeman-Tukey method and estimates the mean of the mean prevalence across studies. It is answering the question "what is the mean prevalence seen across studies"

*Overall rates is calculated by pooling all studies together (i.e. assuming all studies are random samples from the population) and estimates the mean prevalence in the population of patients (ref. Hansen S, Rice K. Exact inference for fixed-effects meta-analysis of proportions. Research Synthesis Methods. 2022;13(2):204-13)

Figure S1: Study flow chart





Figure S2: Risk of Bias

	B1	B2	B3	B4	B5	Overall
4D	Green	Green	Green	Green	Green	Yellow
4S	Yellow	Green	Green	Green	Green	Yellow
A to Z	Green	Green	Green	Green	Green	Green
AFCAPS	Green	Red	Green	Green	Green	Red
ALERT	Green	Green	Green	Green	Green	Green
ALLHAT-LLT	Green	Yellow	Green	Green	Green	Yellow
ALLIANCE	Yellow	Yellow	Green	Yellow	Green	Red
ASCOT-LLA	Green	Green	Green	Green	Green	Green
ASPEN	Yellow	Green	Green	Green	Yellow	Red
AURORA	Yellow	Green	Green	Green	Green	Yellow
CARDS	Green	Green	Green	Yellow	Green	Yellow
CARE	Green	Green	Green	Green	Green	Green
CORONA	Green	Green	Green	Green	Green	Green
EMPATHY	Green	Yellow	Green	Green	Green	Yellow
EWTOPIA-75	Green	Green	Green	Green	Green	Green
FOURIER	Green	Green	Green	Green	Yellow	Yellow
GISSI-HF	Green	Green	Green	Green	Green	Green
GISSI-P	Green	Red	Green	Green	Red	Red
GREACE	Green	Green	Green	Green	Yellow	Yellow
HIJ-PROPER	Yellow	Red	Green	Green	Green	Red
HOPE-3	Green	Green	Green	Green	Green	Green
HPS	Green	Yellow	Green	Green	Green	Yellow
IDEAL	Green	Green	Green	Green	Green	Green
IMPROVE-IT	Yellow	Green	Green	Green	Green	Yellow
J-STARS	Green	Green	Green	Green	Green	Green
JUPITER	Green	Green	Green	Green	Green	Green
LIPID	Green	Green	Green	Green	Green	Green
LIPS	Green	Green	Green	Green	Green	Green
MEGA	Green	Green	Green	Green	Red	Red
Odyssey outcomes	Green	Green	Green	Green	Green	Green
Post CABG	Yellow	Green	Green	Green	Green	Yellow
PROSPER	Green	Green	Green	Green	Green	Green
PROVE-IT	Green	Yellow	Green	Yellow	Red	Red
REAL-CAD	Green	Yellow	Yellow	Green	Yellow	Red
SEARCH	Green	Green	Green	Green	Yellow	Yellow
SEAS	Yellow	Green	Green	Green	Green	Yellow
SHARP	Green	Green	Green	Green	Yellow	Yellow
SPARCL	Yellow	Green	Green	Green	Green	Yellow
TNT	Yellow	Green	Green	Green	Green	Yellow
TRACE RA	Green	Green	Green	Green	Green	Green
Treat stroke to target	Green	Red	Green	Green	Green	Red
WOSCOPS	Green	Green	Green	Green	Green	Green

B1: Risk of bias arising from the randomization process
 B2: Risk of bias due to deviations from intended interventions
 B3: Risk of bias due to missing outcome data
 B4: Risk of bias in measurement of the outcome
 B5: Risk of bias in selection of the reported result


Figure S3: Percentage of RCTs excluding specific predefined patients' group



Blue: Patient group as a clearly defined exclusion criterion. % of trials excluding all patients of this exact group. **Light blue:** Part of patients' group excluded (e.g. only patients with heart failure NYHA III-IV excluded). % of trials excluding a part of this specific patient group. **Green:** Patients' group not clearly mentioned; medical condition circumscribed. % of trials probably excluding this specific patient group. **Grey:** Unknown (no information available; mentioned neither as an inclusion nor as an exclusion criterion)

Women*: Group of premenopausal, of childbearing potential, pregnant or lactating women excluded.
 Kidney failure#: n=1 trial excluded for analysis (all patients on hemodialysis)

Figure S4: Pooled prevalence of patients above 70 years of age



*only data for patients ≥70 years available